Qiagen (QGEN) announces it has submitted an approval application to the FDA for its Erbitux...

|About: Qiagen N.V. (QGEN)|By:, SA News Editor

Qiagen (QGEN) announces it has submitted an approval application to the FDA for its Erbitux treatment for colorectal cancer. The firm says its pipeline of healthcare assays includes a submission in 2012 for an EGFR biomarker test for use with an anticancer medicine for patients with a form of lung cancer. Shares +6.3% premarket. (PR)